Hiroaki Kanzaki
Overview
Explore the profile of Hiroaki Kanzaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
371
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sugimoto A, Saito Y, Wang G, Sun Q, Yin C, Lee K, et al.
Nature
. 2025 Mar;
PMID: 40074890
Hepatic stellate cells (HSCs) have a central pathogenetic role in the development of liver fibrosis. However, their fibrosis-independent and homeostatic functions remain poorly understood. Here we demonstrate that genetic depletion...
2.
Qiang N, Ao J, Nakamura M, Katayama K, Zhang J, Kogure T, et al.
Biochem Pharmacol
. 2025 Feb;
235:116829.
PMID: 40015652
Lenvatinib (LEN)-treated patients with hepatocellular carcinoma (HCC) are frequently accompanied by skeletal muscle loss, which is correlated with poor prognosis. Interactions between tumor and skeletal muscle may play a role...
3.
Fujiwara N, Lopez C, Marsh T, Raman I, Marquez C, Paul S, et al.
Gastroenterology
. 2024 Nov;
168(3):556-567.e7.
PMID: 39521255
Background & Aims: Hepatocellular carcinoma (HCC) risk stratification is an urgent unmet need for cost-effective HCC screening and early detection in patients with cirrhosis to improve poor HCC prognosis. Methods:...
4.
Kanzaki H, Hoshida Y
Clin Mol Hepatol
. 2024 Oct;
31(1):e121-e122.
PMID: 39391909
No abstract available.
5.
Ao J, Qiang N, Kanzaki H, Nakamura M, Kakiuchi R, Zhang J, et al.
Am J Physiol Cell Physiol
. 2024 Sep;
327(4):C1150-C1161.
PMID: 39250819
In the era of immunotherapy, lenvatinib (LEN) still holds an important position in the sequential treatment of advanced hepatocellular carcinoma (HCC). However, the sustained therapeutic effect of LEN is not...
6.
Kanzaki H, Hoshida Y
Clin Mol Hepatol
. 2024 Sep;
31(1):308-310.
PMID: 39218442
No abstract available.
7.
Macias R, Kanzaki H, Berasain C, Avila M, Marin J, Hoshida Y
Am J Pathol
. 2024 Aug;
195(3):422-436.
PMID: 39103092
Cholangiocarcinomas (CCAs) are a heterogeneous group of malignant tumors that originate from the biliary tract. They are usually diagnosed in advanced stages, leading to a poor prognosis for affected patients....
8.
Ozaki T, Yumita S, Ogasawara S, Fujiya M, Tsuchiya T, Yoshino R, et al.
Hepatol Res
. 2024 Jun;
PMID: 38943555
Cytokine release syndrome (CRS) is a systemic inflammatory syndrome that causes fatal circulatory failure due to hypercytokinemia, and subsequent immune cell hyperactivation caused by therapeutic agents, pathogens, cancers, and autoimmune...
9.
Kobayashi K, Ogasawara S, Itobayashi E, Okubo T, Itokawa N, Nakamura K, et al.
Invest New Drugs
. 2024 Jun;
42(4):394-404.
PMID: 38842657
This study aimed to complement the results of the REACH-2 study by prospectively evaluating the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma (HCC) in a real-world setting. This...
10.
Fujiwara K, Kondo T, Fujimoto K, Yumita S, Ogawa K, Ishino T, et al.
J Gastroenterol
. 2024 Apr;
59(6):515-525.
PMID: 38583112
Background: During systemic therapy, the management of portal hypertension (PH)-related complications is vital. This study aimed to clarify factors associated with the incidence and exacerbation of PH-related complications, including the...